BRIEF—Orchard raises $110 million to combat 'bubble baby' disease and other rare conditions

Privately-held gene therapy specialist Orchard Therapeutics has raised $110 million in a series B financing round, to fund development of its rare disease therapy pipeline.

Co-led by Baillie Gifford and ORI Capital, the fundraiser attracted investments also from Temasek and Cowen Healthcare Investments, among others.

The firm says the money will be used to launch OTL-101 for the treatment of ADA-SCID or “bubble baby” disease, in which indication the therapy has received FDA rare pediatric disease designation, but is yet to be approved.

Orchard says it will also expand manufacturing infrastructure and business development activities.

The firm is based in the UK and in California, USA.